---
input_text: "Whole exome sequencing identifies a novel FANCD2 gene splice site mutation
  associated with disease progression in chronic myeloid leukemia: Implication in
  targeted therapy of advanced phase CML. Tyrosine Kinase Inhibitors (TKIs) have significantly
  improved the clinical outcome of BCR-ABL+ Chronic Phase-Chronic Myeloid Leukemia
  (CP-CML). Nonetheless, approximately one-third of the CP-CML patient's progress
  to advanced phases of CML (accelerated and blast phase). Impaired DNA repair including
  mutations in Fanconi anemia (FA) pathway genes are responsible for progression of
  many cancers. Nevertheless, FA-pathways genes have never been reported in myeloid
  cancers. Hence, this study was aimed to discover DNA repair genes associated with
  CML progression. AP-CML patients were subjected to whole exome sequencing along
  with appropriate controls. A novel splice site FANCD2 mutation was detected. FANCD2
  is a well-known FA-pathway gene with established role in DNA repair. This is first
  report of FA-pathway DNA repair genes in myeloid cancers that can serve as a novel
  marker of CML progression to clinically intervene CML progression. Further studies
  are needed to establish the functional role of FANCD2 in CML progression that can
  provide novel insights into CML pathogenesis. This study also indicates that a combination
  TKIs and Poly (ADP-ribose) polymerase (PARP) inhibitors like Olaparib (FDA approved
  anti-cancer drug for FA-pathway gene mutations) could improve the clinical outcome
  CML patients in accelerated and blast-crisis phases of the disease."
raw_completion_output: |-
  primary_disease: Chronic Myeloid Leukemia (CML)
  medical_actions: Whole exome sequencing; Targeted therapy with Tyrosine Kinase Inhibitors (TKIs); Combined treatment with Poly (ADP-ribose) polymerase (PARP) inhibitors
  symptoms: Disease progression to advanced phases
  chemicals: Olaparib
  action_annotation_relationships: Whole exome sequencing PREVENTS Disease progression to advanced phases IN Chronic Myeloid Leukemia (CML); Targeted therapy with Tyrosine Kinase Inhibitors (TKIs) TREATS Disease progression to advanced phases IN Chronic Myeloid Leukemia (CML); Combined treatment (with Olaparib) TREATS Disease progression to advanced phases IN Chronic Myeloid Leukemia (CML)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Combined treatment (with Olaparib) TREATS Disease progression to advanced phases IN Chronic Myeloid Leukemia (CML)

  ===

extracted_object:
  primary_disease: MONDO:0011996
  medical_actions:
    - MAXO:0009004
    - Targeted therapy with Tyrosine Kinase Inhibitors (TKIs)
    - Combined treatment with Poly (ADP-ribose) polymerase (PARP) inhibitors
  symptoms:
    - Disease progression to advanced phases
  chemicals:
    - CHEBI:83766
  action_annotation_relationships:
    - subject: MAXO:0009004
      predicate: PREVENTS
      object: Disease progression to advanced phases
      qualifier: MONDO:0011996
      subject_extension: Whole exome sequencing
    - subject: Targeted therapy
      predicate: TREATS
      object: Disease progression to advanced phases
      qualifier: MONDO:0011996
      subject_extension: CHEBI:38637
    - subject: Combined treatment
      predicate: TREATS
      object: Disease progression to advanced phases
      qualifier: MONDO:0011996
      subject_qualifier: with Olaparib
      subject_extension: CHEBI:83766
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
  - id: MONDO:0008903
    label: Lung Cancer
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0032169
    label: severe infections
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: MONDO:0005109
    label: HIV
  - id: HP:0001622
    label: Preterm delivery
  - id: HP:0100601
    label: Eclampsia
  - id: MONDO:0043455
    label: Hereditary hematological malignancy (HHM)
  - id: MONDO:0043797
    label: Spinal Cord Injury (SCI)
  - id: CHEBI:27306
    label: Vitamin B6
  - id: HP:0001915
    label: aplastic anemia
  - id: MONDO:0001056
    label: Gastric cancer
  - id: MAXO:0001193
    label: Esophagogastroduodenoscopy
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: HP:0012126
    label: Gastric cancer
  - id: MONDO:0005575
    label: Colorectal Cancer
  - id: CHEBI:46345
    label: 5-fluorouracil (5-FU)
  - id: CHEBI:15640
    label: Folinic acid
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: HP:0000026
    label: Testicular failure
  - id: CHEBI:81569
    label: Follicle-stimulating hormone (FSH)
  - id: CHEBI:74539
    label: Luteinizing hormone (LH)
  - id: MONDO:0010651
    label: myelodysplastic syndromes (MDS)
  - id: MAXO:0000079
    label: genetic counseling
  - id: MONDO:0018881
    label: myelodysplastic syndromes
  - id: MAXO:0010033
    label: cord blood transplantation
  - id: CHEBI:50443
    label: hematopoietic stem cells (HSC)
  - id: MONDO:0000159
    label: Bone marrow failure syndromes
  - id: HP:0001903
    label: Anemia
  - id: MONDO:0007959
    label: Medulloblastoma (MB)
  - id: HP:0002885
    label: Medulloblastoma
  - id: CHEBI:3498
    label: CTX
  - id: HP:0000815
    label: Hypergonadotropic hypogonadism
  - id: HP:0000044
    label: Hypogonadotropic hypogonadism
  - id: HP:0008223
    label: Subclinical hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: HP:0000855
    label: Insulin resistance
  - id: HP:0003119
    label: Dyslipidemia
  - id: HP:0002671
    label: Basal cell cancer
  - id: CHEBI:7421
    label: N-acetylcysteine (NAC)
  - id: CHEBI:66919
    label: ruxolitinib
  - id: MAXO:0000757
    label: infusion
  - id: CHEBI:35341
    label: steroids
  - id: MONDO:0011996
    label: Chronic Myeloid Leukemia (CML)
  - id: MAXO:0009004
    label: Whole exome sequencing
  - id: CHEBI:83766
    label: Olaparib
  - id: CHEBI:38637
    label: Tyrosine Kinase Inhibitors (TKIs)
